Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valentis expands licensing with Schering AG
Under the agreement, Valentis has agreed to grant Schering a worldwide license to its GeneSwitch gene regulation and PINC polymer delivery technologies for research purposes on a non-exclusive
Under the agreement, Valentis has agreed to grant Schering a worldwide license to its GeneSwitch gene regulation and PINC polymer delivery technologies for research purposes on a non-exclusive
The lawsuit had been filed in a US federal district court on February 8, 2005, alleging false advertising and unfair competition claims relating to the Nicodrops product. The
InterveXion has received a $3 million grant to conduct clinical trials for the first antibody treatment for addiction to the drug phencyclidine, or PCP. The business development grant
The FDA approval was based on results of a large randomized, double-blind, placebo-controlled study involving 277 patients with pulmonary arterial hypertension (PAH). The study measured the exercise capability
The study, which compared the five-day dosing (320mg once-daily) to the FDA-approved seven-day dosing, achieved its primary endpoint (non-inferior clinical response rate at the follow-up visit), illustrating the
The study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of ALTU-238 in normal healthy volunteers. Altus now plans to initiate a multi-center
Blue Cross is using the ZixVPM (Virtual Private Messenger) to enforce its email security policies in order to ensure secure handling of confidential information to its users, including
If the drug continues in development and ultimately is approved and marketed, Ligand could receive additional milestone payments and double-digit royalties on product sales. Thrombocytopenia (decreased platelet count)
The study showed, 30 days after receiving the stem cells by injection into their hearts, patients improved an average of 41% in their hearts’ pumping efficiency and the
The payment was granted for the identification of a number of lead series for a priority target of this collaboration. Further projects within the multi-target three year collaboration